In Vitro Sciences Names Derek Larkin as New Chief Executive Officer
The In Vitro Sciences (IVS) Board of Directors announced today the placement of Derek M. Larkin as Chief Executive Officer.
AVON, Conn., May 21, 2020 /PRNewswire-PRWeb/ -- The In Vitro Sciences (IVS) Board of Directors announced today the placement of Derek M. Larkin as Chief Executive Officer. This appointment follows a recapitalization event by private equity firm, Sverica Capital Management, LP (Boston and San Francisco) and helps set IVS up for continued national expansion. During the past year IVS, a prominent network of fertility centers, also completed a spin-out from Women's Health USA and acquired Advanced Fertility Care, a Phoenix, Arizona-based fertility clinic.
Derek comes to IVS with more than 20 years of executive leadership experience in both the pharmaceutical and healthcare fields. Most recently, Derek spent nearly 12 years as Chief Executive Officer of Boston IVF, one of the largest in vitro fertilization (IVF) practices in the U.S. In this role, Derek was fundamental in tripling the company's revenue, initiating and launching a national chain of IVF centers and leading one of the largest mergers ever within the IVF category in the U.S. Derek was also instrumental in expanding the scope of the company's capabilities from IVF alone to a comprehensive women's health company, in partnership with other similar surgical specialties.
"We are fortunate to have someone of Derek Larkin's caliber and experience to lead IVS. We are in the midst of transformative growth at IVS, and the addition of Derek to an already veteran team will be immensely valuable as we successfully implement our strategy and continue to grow in the market," said Gregg Osenkowski, a partner at Sverica and a member of the IVS Board of Directors. "We find Derek to be extremely well-suited for this position. He is a proven leader and an experienced CEO and is well-positioned to lead IVS's continued transformation. Derek has a strong strategic track record in implementing change and driving results."
"I'm honored and thrilled to join the team at IVS and to help lead our collective growth efforts. I have deep respect for all the work that has taken place at IVS, and I look forward to working closely with the board, members of the management team, and team members," adds Larkin. "Together, we will mark a new path for growth for IVS."
About In Vitro Sciences
With a 23-year history in the fertility arena and a comprehensive suite of business management services, In Vitro Sciences (IVS) partners with reproductive endocrinology practices across the United States. IVS got its start in partnership with Women's Health USA, a national management service organization supporting more than 600 ObGyn providers around the U.S. IVS offers strategic management services for independent practices, including:
implementing creative growth strategies supporting streamlined operational costs, payer alignment, merger and acquisition plans, marketing, and risk management services. Its unique partnership model enables physicians and physician groups to maintain their independence while leveraging the resources of a national organization.
SOURCE In Vitro Sciences
Share this article